Lichen planopilaris

Published on 19/03/2015 by admin

Filed under Dermatology

Last modified 19/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 2 (3 votes)

This article have been viewed 3501 times

Lichen planopilaris

Anwar Al Hammadi and Eric Berkowitz

Evidence Levels:  A Double-blind study  B Clinical trial ≥ 20 subjects  C Clinical trial < 20 subjects  D Series ≥ 5 subjects  E Anecdotal case reports

image

Lichen planopilaris (LPP), also known as follicular lichen planus, is a clinical syndrome consisting of lichen planus (LP) associated with cicatricial scalp alopecia. The condition is more common in women, and presents with perifollicular erythema and keratotic plugs at the margins of the expanding alopecia. The follicular involvement is limited to the infundibulum and the isthmus, both demonstrating lichenoid inflammation. The main complications of follicular lichen planus are atrophy and scarring, with permanent hair loss. Three forms of LPP are recognized, including classic LPP; Graham–Little syndrome, characterized by the triad of multifocal scalp cicatricial alopecia, non-scarring alopecia of the axilla and/or groin, and keratotic follicular papules; and frontal fibrosing alopecia that affects mainly postmenopausal women and appears as cicatricial alopecia of the frontoparietal hairline and is associated with non-scarring alopecia of the eyebrows.

Management strategy

Therapeutic management for LPP is challenging. However, if the associated inflammation can be controlled in its early stages, follicular units may be preserved and hair regrowth may be possible. A good therapeutic response would include a reduction in associated symptoms along with stabilization of the disease and some regrowth of hair in the active perimeter of the alopecic patch. For the most part, therapeutic reports are anecdotal. Oral antihistamines may be used to control pruritus, and high-potency topical corticosteroids are used to control the inflammation in early lesions. Intralesional injections of 3–5 mg/mL of triamcinolone acetonide are effective in well-developed lesions. Hydroxychloroquine may be efficacious. Retinoids have demonstrated some effect in the treatment of LP and therefore provide a possible alternative to corticosteroid treatment. Other agents that have been reported to be of use are cyclosporine and mycophenolate mofetil. There is some rationale for trying biologic agents such as tumor necrosis factor (TNF)-blocking agents for this condition.

Specific investigations

First-line therapies

Buy Membership for Dermatology Category to continue reading. Learn more here
imageHigh-potency corticosteroids